Diversity of clinical presentation and virological characteristics of hepatitis delta in different regions world-wide: results of the Hepatitis Delta International network

Wranke, A.; Hardtke, Svenja; Borzacov, Lourdes Maria Pinheiro; Paraná, Raymundo; Lobato, Cirley; Salehiniya, Hamid; Ceauşu, Emanoil; Dalekos, Georgios N.; Rizzetto, M.; Turcanu, Adela; Niro, Grazia; Hayden, Tonya; Abbas, Minaam; Ingiliz, Patrick; Buti, María; Ferenci, Péter; Vanwolleghem, Thomas; Moţoc, Adriana; Abbas, Zaigham; Yurdaydın, Cihan; Mp, Manns; Wedemeyer, Heiner; Serrano, B Calle; Wöbse, M.; Heidrich, B.; Muche, Marion; Gatselis, Nikolaos; Zachou, Kalliopi; Smedile, A; Gish, Robert G.; Obretin, D.; Stern, Richard; Ho, Edith Y.; Michielsen, P.; Valentina, O.D.; Lubna, Farheen; Fontana, R.

doi:10.1016/s0168-8278(17)30824-3

Cited by 3 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In areas where hepatitis D virus (HDV) co‐infection is common (e.g. Mongolia or the Amazon in Brazil or Peru) among persons with HBV infection, testing for HDV DNA is also needed, in view of specific treatment considerations .…”

Section: Discussionmentioning

confidence: 99%

How far are we from viral hepatitis elimination service coverage targets?

2018

View full text Add to dashboard Cite

IntroductionIn 2016, the Global Health Sector Strategy (GHSS) on viral hepatitis called for elimination of viral hepatitis as a major public health threat by 2030 (i.e. 90% reduction in incidence and 65% in mortality). In 2017, WHO's first‐ever Global Hepatitis Report presented the baseline values for each of the core indicators of the strategy. We review the challenges and opportunities that lie ahead in order to reach the 2030 service coverage targets.DiscussionThree‐dose coverage of hepatitis B vaccine in infancy reached 84% in 2015 (2030 target: 90%); however, only 39% received the timely birth dose (2030 target: 90%). Blood safety (97% of blood units screened with quality assurance, 2030 target: 100%) and injection safety (5% unsafe injections, 2030 target: 0%) had made substantial progress while harm reduction fell short (27 syringe and needle sets distributed per person who injects drugs per year, 2030 target: 300). Worldwide, 9% and 20% of the HBV‐ and HCV‐infected population respectively, were aware of their status (2030 targets: 90%). In the short term, to reach the 2020 target of diagnosing 50% of those infected, 107 million HBV infected persons and 15 million HCV infected persons should be urgently diagnosed. Overall, in 2015, less than 10% of known infected persons were on HBV treatment or had started HCV treatment (2030 targets: 80%).ConclusionsThe prevention component of elimination is on track with respect to hepatitis B vaccination, blood safety, and injection safety. However, coverage of the hepatitis B vaccine timely birth dose requires a substantial increase, particularly in sub‐Saharan Africa, and harm reduction needs to be taken to scale as injecting drug use accounts for a third of mortality from HCV infection. A promising but limited start in hepatitis testing and treatment needs to be followed by immediate and sustained action so that we reach the service coverage targets required to achieve elimination by 2030. Treating persons coinfected with HIV and hepatitis viruses is particularly urgent and needs to be promoted in the context of the HIV response.

show abstract

Section: Discussionmentioning

confidence: 99%

How far are we from viral hepatitis elimination service coverage targets?

2018

View full text Add to dashboard Cite

show abstract

“…There are thought to be 10-15 million HDV carriers worldwide as a result of the projected co-infection of 5% of HBsAg carriers with HDV 12 . Several investigations have demonstrated that HDV infection worsens the course of HBV co-infection, hastening the development of cirrhosis and causing early liver function decompensation in comparison to HBV mono-infection 13,14,15 . According to epidemiological research, HDV is widespread and that its local incidence depends on the prevalence of HBV 15 .…”

Section: Introductionmentioning

confidence: 99%

Prevalence of Hepatitis D virus infection among Hepatitis B virus surface antigen positive children attending two selected Hospitals in Jos, Nigeria

Chindah, Chingarum Evelyn,

Lohya Nimzing,

Kukwa Queen

et al. 2024

Magna Sci. Adv. Biol. Pharm.

View full text Add to dashboard Cite

Hepatitis B virus is a member of Hepadnaviridae family that cause liver infections in humans. These viral infections are characteristically linked with cirrhosis, chronic hepatitis, and hepatocellular carcinoma that are the leading cause of morbidity and mortality in the population of developing countries including Nigeria. Young children and newborns are more likely to have liver damage early in life and become chronic HBV carriers. This study identified the frequency of hepatitis B and D co-infection in children visiting the emergency pediatric units of Plateau State Specialist Hospital and Bingham University Teaching Hospital in Jos, Plateau State, Nigeria. The virus was screened using immunochromatographic Skytec® HBsAg test strips and Alere chase buffer for the qualitative detection of HBsAg in serum. HBsAg positive samples were confirmed using HBsAg Monolisa ELISA kit. Using an Italian HDV ELISA kit, samples that tested positive for HBsAg were further examined to evaluate the presence of HDV co-infection. The finding of this study revealed that 4.4% of children had HBsAg markers on their bodies. None of the children with HBV infection were co-infected with HDV. The HBV prevalence was found to be highest in children aged 6 to 10 years. Females had higher levels of HBV seropositivity (5.5%). Risk factors in children included birthplace (native households), failure to check children's HBV status after immunization, and history of jaundice. To properly manage and prevent this infection, it is advised that children should be promptly immunized at birth, their HBV status should be confirmed following immunization and they should be revaccinated if necessary.

show abstract

Hepatitis D virus in Africa: several unmet needs

Manns

2017

The Lancet Global Health

View full text Add to dashboard Cite

Diversity of clinical presentation and virological characteristics of hepatitis delta in different regions world-wide: results of the Hepatitis Delta International network

Cited by 3 publications

References 0 publications

How far are we from viral hepatitis elimination service coverage targets?

How far are we from viral hepatitis elimination service coverage targets?

Prevalence of Hepatitis D virus infection among Hepatitis B virus surface antigen positive children attending two selected Hospitals in Jos, Nigeria

Hepatitis D virus in Africa: several unmet needs

Contact Info

Product

Resources

About